16 results on '"Besselink, Marc G H"'
Search Results
2. Fluid hydration to prevent post-ERCP pancreatitis in average- to high-risk patients receiving prophylactic rectal NSAIDs (FLUYT trial): study protocol for a randomized controlled trial
- Author
-
Smeets, Xavier J. N. M., da Costa, David W., Fockens, Paul, Mulder, Chris J. J., Timmer, Robin, Kievit, Wietske, Zegers, Marieke, Bruno, Marco J., Besselink, Marc G. H., Vleggaar, Frank P., van der Hulst, Rene W. M., Poen, Alexander C., Heine, Gerbrand D. N., Venneman, Niels G., Kolkman, Jeroen J., Baak, Lubbertus C., Römkens, Tessa E. H., van Dijk, Sven M., Hallensleben, Nora D. L., van de Vrie, Wim, Seerden, Tom C. J., Tan, Adriaan C. I. T. L., Voorburg, Annet M. C. J., Poley, Jan-Werner, Witteman, Ben J., Bhalla, Abha, Hadithi, Muhammed, Thijs, Willem J., Schwartz, Matthijs P., Vrolijk, Jan Maarten, Verdonk, Robert C., van Delft, Foke, Keulemans, Yolande, van Goor, Harry, Drenth, Joost P. H., van Geenen, Erwin J. M., and for the Dutch Pancreatitis Study Group
- Published
- 2018
- Full Text
- View/download PDF
3. Fluid hydration to prevent post-ERCP pancreatitis in average- to high-risk patients receiving prophylactic rectal NSAIDs (FLUYT trial) : study protocol for a randomized controlled trial
- Author
-
Smeets, Xavier J N M, da Costa, David W, Fockens, Paul, Mulder, Chris J J, Timmer, Robin, Kievit, Wietske, Zegers, Marieke, Bruno, Marco J, Besselink, Marc G H, Vleggaar, Frank P, van der Hulst, Rene W M, Poen, Alexander C, Heine, Gerbrand D N, Venneman, Niels G, Kolkman, Jeroen J, Baak, Lubbertus C, Römkens, Tessa E H, van Dijk, Sven M, Hallensleben, Nora D L, van de Vrie, Wim, Seerden, Tom C J, Tan, Adriaan C I T L, Voorburg, Annet M C J, Poley, Jan-Werner, Witteman, Ben J, Bhalla, Abha, Hadithi, Muhammed, Thijs, Willem J, Schwartz, Matthijs P, Vrolijk, Jan Maarten, Verdonk, Robert C, van Delft, Foke, Keulemans, Yolande, van Goor, Harry, Drenth, Joost P H, van Geenen, Erwin J M, Dutch Pancreatitis Study Group, Smeets, Xavier J N M, da Costa, David W, Fockens, Paul, Mulder, Chris J J, Timmer, Robin, Kievit, Wietske, Zegers, Marieke, Bruno, Marco J, Besselink, Marc G H, Vleggaar, Frank P, van der Hulst, Rene W M, Poen, Alexander C, Heine, Gerbrand D N, Venneman, Niels G, Kolkman, Jeroen J, Baak, Lubbertus C, Römkens, Tessa E H, van Dijk, Sven M, Hallensleben, Nora D L, van de Vrie, Wim, Seerden, Tom C J, Tan, Adriaan C I T L, Voorburg, Annet M C J, Poley, Jan-Werner, Witteman, Ben J, Bhalla, Abha, Hadithi, Muhammed, Thijs, Willem J, Schwartz, Matthijs P, Vrolijk, Jan Maarten, Verdonk, Robert C, van Delft, Foke, Keulemans, Yolande, van Goor, Harry, Drenth, Joost P H, van Geenen, Erwin J M, and Dutch Pancreatitis Study Group
- Published
- 2018
4. Fluid hydration to prevent post-ERCP pancreatitis in average- to high-risk patients receiving prophylactic rectal NSAIDs (FLUYT trial): study protocol for a randomized controlled trial
- Author
-
Arts-assistenten Radiologie, MS CGO, Cancer, Smeets, Xavier J N M, da Costa, David W, Fockens, Paul, Mulder, Chris J J, Timmer, Robin, Kievit, Wietske, Zegers, Marieke, Bruno, Marco J, Besselink, Marc G H, Vleggaar, Frank P, van der Hulst, Rene W M, Poen, Alexander C, Heine, Gerbrand D N, Venneman, Niels G, Kolkman, Jeroen J, Baak, Lubbertus C, Römkens, Tessa E H, van Dijk, Sven M, Hallensleben, Nora D L, van de Vrie, Wim, Seerden, Tom C J, Tan, Adriaan C I T L, Voorburg, Annet M C J, Poley, Jan-Werner, Witteman, Ben J, Bhalla, Abha, Hadithi, Muhammed, Thijs, Willem J, Schwartz, Matthijs P, Vrolijk, Jan Maarten, Verdonk, Robert C, van Delft, Foke, Keulemans, Yolande, van Goor, Harry, Drenth, Joost P H, van Geenen, Erwin J M, Dutch Pancreatitis Study Group, Arts-assistenten Radiologie, MS CGO, Cancer, Smeets, Xavier J N M, da Costa, David W, Fockens, Paul, Mulder, Chris J J, Timmer, Robin, Kievit, Wietske, Zegers, Marieke, Bruno, Marco J, Besselink, Marc G H, Vleggaar, Frank P, van der Hulst, Rene W M, Poen, Alexander C, Heine, Gerbrand D N, Venneman, Niels G, Kolkman, Jeroen J, Baak, Lubbertus C, Römkens, Tessa E H, van Dijk, Sven M, Hallensleben, Nora D L, van de Vrie, Wim, Seerden, Tom C J, Tan, Adriaan C I T L, Voorburg, Annet M C J, Poley, Jan-Werner, Witteman, Ben J, Bhalla, Abha, Hadithi, Muhammed, Thijs, Willem J, Schwartz, Matthijs P, Vrolijk, Jan Maarten, Verdonk, Robert C, van Delft, Foke, Keulemans, Yolande, van Goor, Harry, Drenth, Joost P H, van Geenen, Erwin J M, and Dutch Pancreatitis Study Group
- Published
- 2018
5. Minimally invasive versus open distal pancreatectomy (LEOPARD) : study protocol for a randomized controlled trial
- Author
-
de Rooij, Thijs, van Hilst, Jony, Vogel, Jantien A, van Santvoort, Hjalmar C, de Boer, Marieke T., Boerma, Djamila, van den Boezem, Peter B., Bonsing, Bert A., Bosscha, Koop, Coene, Peter-Paul, Daams, Freek, van Dam, Ronald M., Dijkgraaf, Marcel G. W., van Eijck, Casper H., Festen, Sebastiaan, Gerhards, Michael F., Groot Koerkamp, Bas, Hagendoorn, Jeroen, van der Harst, Erwin, de Hingh, Ignace H., Dejong, Cees H., Kazemier, Geert, Klaase, Joost M., de Kleine, Ruben H J, van Laarhoven, Cornelis J., Lips, Daan J., Luyer, Misha Dp, Molenaar, I Quintus, Nieuwenhuijs, Vincent B., Patijn, Gijs A., Roos, Daphne, Scheepers, Joris Jg, Van Der Schelling, George P., Steenvoorde, Pascal, Swijnenburg, Rutger-Jan, Wijsman, Jan H, Abu Hilal, Moh'd, Busch, Olivier R C, Besselink, Marc G H, Dutch Pancreatic Cancer Group, de Rooij, Thijs, van Hilst, Jony, Vogel, Jantien A, van Santvoort, Hjalmar C, de Boer, Marieke T., Boerma, Djamila, van den Boezem, Peter B., Bonsing, Bert A., Bosscha, Koop, Coene, Peter-Paul, Daams, Freek, van Dam, Ronald M., Dijkgraaf, Marcel G. W., van Eijck, Casper H., Festen, Sebastiaan, Gerhards, Michael F., Groot Koerkamp, Bas, Hagendoorn, Jeroen, van der Harst, Erwin, de Hingh, Ignace H., Dejong, Cees H., Kazemier, Geert, Klaase, Joost M., de Kleine, Ruben H J, van Laarhoven, Cornelis J., Lips, Daan J., Luyer, Misha Dp, Molenaar, I Quintus, Nieuwenhuijs, Vincent B., Patijn, Gijs A., Roos, Daphne, Scheepers, Joris Jg, Van Der Schelling, George P., Steenvoorde, Pascal, Swijnenburg, Rutger-Jan, Wijsman, Jan H, Abu Hilal, Moh'd, Busch, Olivier R C, Besselink, Marc G H, and Dutch Pancreatic Cancer Group
- Published
- 2017
6. Minimally invasive versus open distal pancreatectomy (LEOPARD): study protocol for a randomized controlled trial
- Author
-
MS CGO, Cancer, de Rooij, Thijs, van Hilst, Jony, Vogel, Jantien A, van Santvoort, Hjalmar C, de Boer, Marieke T., Boerma, Djamila, van den Boezem, Peter B., Bonsing, Bert A., Bosscha, Koop, Coene, Peter-Paul, Daams, Freek, van Dam, Ronald M., Dijkgraaf, Marcel G. W., van Eijck, Casper H., Festen, Sebastiaan, Gerhards, Michael F., Groot Koerkamp, Bas, Hagendoorn, Jeroen, van der Harst, Erwin, de Hingh, Ignace H., Dejong, Cees H., Kazemier, Geert, Klaase, Joost M., de Kleine, Ruben H J, van Laarhoven, Cornelis J., Lips, Daan J., Luyer, Misha Dp, Molenaar, I Quintus, Nieuwenhuijs, Vincent B., Patijn, Gijs A., Roos, Daphne, Scheepers, Joris Jg, Van Der Schelling, George P., Steenvoorde, Pascal, Swijnenburg, Rutger-Jan, Wijsman, Jan H, Abu Hilal, Moh'd, Busch, Olivier R C, Besselink, Marc G H, Dutch Pancreatic Cancer Group, MS CGO, Cancer, de Rooij, Thijs, van Hilst, Jony, Vogel, Jantien A, van Santvoort, Hjalmar C, de Boer, Marieke T., Boerma, Djamila, van den Boezem, Peter B., Bonsing, Bert A., Bosscha, Koop, Coene, Peter-Paul, Daams, Freek, van Dam, Ronald M., Dijkgraaf, Marcel G. W., van Eijck, Casper H., Festen, Sebastiaan, Gerhards, Michael F., Groot Koerkamp, Bas, Hagendoorn, Jeroen, van der Harst, Erwin, de Hingh, Ignace H., Dejong, Cees H., Kazemier, Geert, Klaase, Joost M., de Kleine, Ruben H J, van Laarhoven, Cornelis J., Lips, Daan J., Luyer, Misha Dp, Molenaar, I Quintus, Nieuwenhuijs, Vincent B., Patijn, Gijs A., Roos, Daphne, Scheepers, Joris Jg, Van Der Schelling, George P., Steenvoorde, Pascal, Swijnenburg, Rutger-Jan, Wijsman, Jan H, Abu Hilal, Moh'd, Busch, Olivier R C, Besselink, Marc G H, and Dutch Pancreatic Cancer Group
- Published
- 2017
7. Early biliary decompression versus conservative treatment in acute biliary pancreatitis (APEC trial) : Study protocol for a randomized controlled trial
- Author
-
Schepers, Nicolien J., Bakker, Olaf J., Besselink, Marc G H, Bollen, Thomas L., Dijkgraaf, Marcel G W, van Eijck, Casper H J, Fockens, Paul, van Geenen, Erwin J M, van Grinsven, Janneke, Hallensleben, Nora D L, Hansen, Bettina E., van Santvoort, Hjalmar C., Timmer, Robin, Anten, Marie Paule G F, Bolwerk, Clemens J M, van Delft, Foke, van Dullemen, Hendrik M., Erkelens, G. Willemien, van Hooft, Jeanin E., Laheij, Robert, van der Hulst, René W M, Jansen, Jeroen M., Kubben, Frank J G M, Kuiken, Sjoerd D., Perk, Lars E., de Ridder, Rogier J J, Rijk, Marno C M, Römkens, Tessa E H, Schoon, Erik J., Schwartz, Matthijs P., Spanier, B. W Marcel, Tan, Adriaan C I T L, Thijs, Willem J., Venneman, Niels G., Vleggaar, Frank P., van de Vrie, Wim, Witteman, Ben J., Gooszen, Hein G., Bruno, Marco J., Schepers, Nicolien J., Bakker, Olaf J., Besselink, Marc G H, Bollen, Thomas L., Dijkgraaf, Marcel G W, van Eijck, Casper H J, Fockens, Paul, van Geenen, Erwin J M, van Grinsven, Janneke, Hallensleben, Nora D L, Hansen, Bettina E., van Santvoort, Hjalmar C., Timmer, Robin, Anten, Marie Paule G F, Bolwerk, Clemens J M, van Delft, Foke, van Dullemen, Hendrik M., Erkelens, G. Willemien, van Hooft, Jeanin E., Laheij, Robert, van der Hulst, René W M, Jansen, Jeroen M., Kubben, Frank J G M, Kuiken, Sjoerd D., Perk, Lars E., de Ridder, Rogier J J, Rijk, Marno C M, Römkens, Tessa E H, Schoon, Erik J., Schwartz, Matthijs P., Spanier, B. W Marcel, Tan, Adriaan C I T L, Thijs, Willem J., Venneman, Niels G., Vleggaar, Frank P., van de Vrie, Wim, Witteman, Ben J., Gooszen, Hein G., and Bruno, Marco J.
- Published
- 2016
8. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial.
- Author
-
Versteijne, Eva, van Eijck, Casper H. J., Punt, Cornelis J. A., Suker, Mustafa, Zwinderman, Aeilko H., Dohmen, Miriam A. C., Groothuis, Karin B. C., Busch, Oliver R. C., Besselink, Marc G. H., de Hingh, Ignace H. J. T., ten Tije, Albert J., Patijn, Gijs A., Bonsing, Bert A., de Vos-Geelen, Judith, Klaase, Joost M., Festen, Sebastiaan, Boerma, Djamila, Erdmann, Joris I., Quintus. Molenaar, I., and van der Harst, Erwin
- Subjects
PANCREATIC cancer diagnosis ,PANCREATIC cancer treatment ,PREANESTHETIC medication ,CHEMORADIOTHERAPY ,ABDOMINAL surgery ,CANCER treatment ,ADENOCARCINOMA ,ANTHROPOMETRY ,ANTIMETABOLITES ,ANTINEOPLASTIC agents ,CANCER relapse ,CLINICAL trials ,COMBINED modality therapy ,COMPARATIVE studies ,DRUG administration ,EXPERIMENTAL design ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH protocols ,PANCREATIC tumors ,PANCREATECTOMY ,PROGNOSIS ,RESEARCH ,TIME ,TUMOR classification ,EVALUATION research ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,DEOXYCYTIDINE ,KAPLAN-Meier estimator ,ARTHRITIS Impact Measurement Scales ,TUMOR treatment - Abstract
Background: Pancreatic cancer is the fourth largest cause of cancer death in the United States and Europe with over 100,000 deaths per year in Europe alone. The overall 5-year survival ranges from 2-7 % and has hardly improved over the last two decades. Approximately 15 % of all patients have resectable disease at diagnosis, and of those, only a subgroup has a resectable tumour at surgical exploration. Data from cohort studies have suggested that outcome can be improved by preoperative radiochemotherapy, but data from well-designed randomized studies are lacking. Our PREOPANC phase III trial aims to test the hypothesis that median overall survival of patients with resectable or borderline resectable pancreatic cancer can be improved with preoperative radiochemotherapy.Methods/design: The PREOPANC trial is a randomized, controlled, multicentric superiority trial, initiated by the Dutch Pancreatic Cancer Group. Patients with (borderline) resectable pancreatic cancer are randomized to A: direct explorative laparotomy or B: after negative diagnostic laparoscopy, preoperative radiochemotherapy, followed by explorative laparotomy. A hypofractionated radiation scheme of 15 fractions of 2.4 gray (Gy) is combined with a course of gemcitabine, 1,000 mg/m(2)/dose on days 1, 8 and 15, preceded and followed by a modified course of gemcitabine. The target volumes of radiation are delineated on a 4D CT scan, where at least 95 % of the prescribed dose of 36 Gy in 15 fractions should cover 98 % of the planning target volume. Standard adjuvant chemotherapy is administered in both treatment arms after resection (six cycles in arm A and four in arm B). In total, 244 patients will be randomized in 17 hospitals in the Netherlands. The primary endpoint is overall survival by intention to treat. Secondary endpoints are (R0) resection rate, disease-free survival, time to locoregional recurrence or distant metastases and perioperative complications. Secondary endpoints for the experimental arm are toxicity and radiologic and pathologic response.Discussion: The PREOPANC trial is designed to investigate whether preoperative radiochemotherapy improves overall survival by means of increased (R0) resection rates in patients with resectable or borderline resectable pancreatic cancer.Trial Registration: Trial open for accrual: 3 April 2013 The Netherlands National Trial Register - NTR3709 (8 November 2012) EU Clinical Trials Register - 2012-003181-40 (11 December 2012). [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
9. Transluminal endoscopic step-up approach versus minimally invasive surgical step-up approach in patients with infected necrotising pancreatitis (TENSION trial): design and rationale of a randomised controlled multicenter trial [ISRCTN09186711].
- Author
-
van Brunschot, Sandra, van Grinsven, Janneke, Voermans, Rogier P., Bakker, Olaf J., Besselink, Marc G. H., Boermeester, Marja A., Bollen, Thomas L., Bosscha, Koop, Bouwense, Stefan A., Bruno, Marco J., Cappendijk, Vincent C., Consten, Esther C., Dejong, Cornelis H., Dijkgraaf, Marcel G. W., van Eijck, Casper H., Erkelens, G. Willemien, van Goor, Harry, Hadithi, Mohammed, Haveman, Jan-Willem, and Hofker, Sijbrand H.
- Subjects
RANDOMIZED controlled trials ,LENGTH of stay in hospitals ,LASER endoscopy ,TRANSLUMINAL angioplasty ,EXOCRINE glands - Abstract
Background Infected necrotising pancreatitis is a potentially lethal disease that nearly always requires intervention. Traditionally, primary open necrosectomy has been the treatment of choice. In recent years, the surgical step-up approach, consisting of percutaneous catheter drainage followed, if necessary, by (minimally invasive) surgical necrosectomy has become the standard of care. A promising minimally invasive alternative is the endoscopic transluminal step-up approach. This approach consists of endoscopic transluminal drainage followed, if necessary, by endoscopic transluminal necrosectomy. We hypothesise that the less invasive endoscopic step-up approach is superior to the surgical step-up approach in terms of clinical and economic outcomes. Methods/design The TENSION trial is a randomised controlled, parallel-group superiority multicenter trial. Patients with (suspected) infected necrotising pancreatitis with an indication for intervention and in whom both treatment modalities are deemed possible, will be randomised to either an endoscopic transluminal or a surgical step-up approach. During a 4 year study period, 98 patients will be enrolled from 24 hospitals of the Dutch Pancreatitis Study Group. The primary endpoint is a composite of death and major complications within 6 months following randomisation. Secondary endpoints include complications such as pancreaticocutaneous fistula, exocrine or endocrine pancreatic insufficiency, need for additional radiological, endoscopic or surgical intervention, the need for necrosectomy after drainage, the number of (re-)interventions, quality of life, and total direct and indirect costs. Discussion The TENSION trial will answer the question whether an endoscopic step-up approach reduces the combined primary endpoint of death and major complications, as well as hospital stay and related costs compared with a surgical step-up approach in patients with infected necrotising pancreatitis. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
10. Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus open transthoracic esophagectomy for resectable esophageal cancer, a randomized controlled trial (ROBOT trial).
- Author
-
van der Sluis, Pieter C., Ruurda, Jelle P., der Horst, Sylvia van, Verhage, Roy J. J., Besselink, Marc G. H., Prins, Margriet J. D., Haverkamp, Leonie, Schippers, Carlo, Borel Rinkes, Inne H. M., Joore, Hans C. A., ten Kate, Fiebo J. W., Koffijberg, Hendrik, Kroese, Christiaan C., van Leeuwen, Maarten S., Lolkema, Martijn P. J. K., Reerink, Onne, Schipper, Marguerite E. I., Steenhagen, Elles, Vleggaar, Frank P., and Voest, Emile E.
- Subjects
ESOPHAGEAL cancer ,ESOPHAGECTOMY ,LYMPH nodes ,ESOPHAGEAL surgery ,CANCER treatment complications ,CLINICAL trials ,RANDOMIZED controlled trials - Abstract
Background: For esophageal cancer patients, radical esophagolymphadenectomy is the cornerstone of multimodality treatment with curative intent. Transthoracic esophagectomy is the preferred surgical approach worldwide allowing for en-bloc resection of the tumor with the surrounding lymph nodes. However, the percentage of cardiopulmonary complications associated with the transthoracic approach is high (50 to 70%). Recent studies have shown that robot-assisted minimally invasive thoraco-laparoscopic esophagectomy (RATE) is at least equivalent to the open transthoracic approach for esophageal cancer in terms of short-term oncological outcomes. RATE was accompanied with reduced blood loss, shorter ICU stay and improved lymph node retrieval compared with open esophagectomy, and the pulmonary complication rate, hospital stay and perioperative mortality were comparable. The objective is to evaluate the efficacy, risks, quality of life and cost-effectiveness of RATE as an alternative to open transthoracic esophagectomy for treatment of esophageal cancer. Methods/design: This is an investigator-initiated and investigator-driven monocenter randomized controlled parallel-group, superiority trial. All adult patients (age ⩾18 and ⩽80 years) with histologically proven, surgically resectable (cT1-4a, N0-3, M0) esophageal carcinoma of the intrathoracic esophagus and with European Clinical Oncology Group performance status 0, 1 or 2 will be assessed for eligibility and included after obtaining informed consent. Patients (n = 112) with resectable esophageal cancer are randomized in the outpatient department to either RATE (n = 56) or open three-stage transthoracic esophageal resection (n = 56). The primary outcome of this study is the percentage of overall complications (grade 2 and higher) as stated by the modified Clavien-Dindo classification of surgical complications. Discussion: This is the first randomized controlled trial designed to compare RATE with open transthoracic esophagectomy as surgical treatment for resectable esophageal cancer. If our hypothesis is proven correct, RATE will result in a lower percentage of postoperative complications, lower blood loss, and shorter hospital stay, but with at least similar oncologic outcomes and better postoperative quality of life compared with open transthoracic esophagectomy. The study started in January 2012. Follow-up will be 5 years. Short-term results will be analyzed and published after discharge of the last randomized patient. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
11. Minimally invasive 'step-up approach' versus maximal necrosectomy in patients with acute necrotising pancreatitis (PANTER trial): design and rationale of a randomised controlled multicenter trial [ISRCTN38327949].
- Author
-
Besselink, Marc G. H., van Santvoort, Hjalmar C., Nieuwenhuijs, Vincent B., Boermeester, Marja A., Bollen, Thomas L., Buskens, Erik, Dejong, Cornelis H. C., van Eijck, Casper H. J., van Goor, Harry, Hofker, Sijbrand S., Lameris, Johan S., van Leeuwen, Maarten S., Ploeg, Rutger J., van Ramshorst, Bert, Schaapherder, Alexander F. M., Cuesta, Miguel A., Consten, Esther C. J., Gouma, Dirk J., van der Harst, Erwin, and Hesselink, Eric J.
- Subjects
NECROTIZING pancreatitis ,ABDOMINAL surgery ,CLINICAL trials ,IRRIGATION (Medicine) ,DEBRIDEMENT ,THERAPEUTICS - Abstract
Background: The initial treatment of acute necrotizing pancreatitis is conservative. Intervention is indicated in patients with (suspected) infected necrotizing pancreatitis. In the Netherlands, the standard intervention is necrosectomy by laparotomy followed by continuous postoperative lavage (CPL). In recent years several minimally invasive strategies have been introduced. So far, these strategies have never been compared in a randomised controlled trial. The PANTER study (PAncreatitis, Necrosectomy versus sTEp up appRoach) was conceived to yield the evidence needed for a considered policy decision. Methods/design: 88 patients with (suspected) infected necrotizing pancreatitis will be randomly allocated to either group A) minimally invasive 'step-up approach' starting with drainage followed, if necessary, by videoscopic assisted retroperitoneal debridement (VARD) or group B) maximal necrosectomy by laparotomy. Both procedures are followed by CPL. Patients will be recruited from 20 hospitals, including all Dutch university medical centres, over a 3-year period. The primary endpoint is the proportion of patients suffering from postoperative major morbidity and mortality. Secondary endpoints are complications, new onset sepsis, length of hospital and intensive care stay, quality of life and total (direct and indirect) costs. To demonstrate that the 'step-up approach' can reduce the major morbidity and mortality rate from 45 to 16%, with 80% power at 5% alpha, a total sample size of 88 patients was calculated. Discussion: The PANTER-study is a randomised controlled trial that will provide evidence on the merits of a minimally invasive 'step-up approach' in patients with (suspected) infected necrotizing pancreatitis. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
12. Probiotic prophylaxis in patients with predicted severe acute pancreatitis (PROPATRIA): design and rationale of a double-blind, placebo-controlled randomised multicenter trial [ISRCTN38327949].
- Author
-
Besselink, Marc G. H., Timmerman, Harro M., Buskens, Erik, Nieuwenhuijs, Vincent B., Akkermans, Louis M. A., and Gooszen, Hein G.
- Subjects
PROBIOTICS ,INFECTION prevention ,PANCREATITIS ,PLACEBOS ,UNIVERSITY hospitals - Abstract
Background: Infectious complications are the major cause of death in acute pancreatitis. Small bowel bacterial overgrowth and subsequent bacterial translocation are held responsible for the vast majority of these infections. Goal of this study is to determine whether selected probiotics are capable of preventing infectious complications without the disadvantages of antibiotic prophylaxis; antibiotic resistance and fungal overgrowth. Methods/design: PROPATRIA is a double-blind, placebo-controlled randomised multicenter trial in which 200 patients will be randomly allocated to a multispecies probiotic preparation (Ecologic 641) or placebo. The study is performed in all 8 Dutch University Hospitals and 7 non-University hospitals. The study-product is administered twice daily through a nasojejunal tube for 28 days or until discharge. Patients eligible for randomisation are adult patients with a first onset of predicted severe acute pancreatitis: Imrie criteria 3 or more, CRP 150 mg/L or more, APACHE II score 8 or more. Exclusion criteria are post-ERCP pancreatitis, malignancy, infection/sepsis caused by a second disease, intra-operative diagnosis of pancreatitis and use of probiotics during the study. Administration of the study product is started within 72 hours after onset of abdominal pain. The primary endpoint is the total number of infectious complications. Secondary endpoints are mortality, necrosectomy, antibiotic resistance, hospital stay and adverse events. To demonstrate that probiotic prophylaxis reduces the proportion of patients with infectious complications from 50% to 30%, with alpha 0,05 and power 80%, a total sample size of 200 patients was calculated. Conclusion: The PROPATRIA study is aimed to show a reduction in infectious complications due to early enteral use of multispecies probiotics in severe acute pancreatitis. [ABSTRACT FROM AUTHOR]
- Published
- 2004
13. Preoperative endoscopic versus percutaneous transhepatic biliary drainage in potentially resectable perihilar cholangiocarcinoma (DRAINAGE trial): design and rationale of a randomized controlled trial.
- Author
-
Wiggers, Jimme K, Coelen, Robert Js, Rauws, Erik Aj, van Delden, Otto M, van Eijck, Casper Hj, de Jonge, Jeroen, Porte, Robert J, Buis, Carlijn I, Dejong, Cornelis Hc, Molenaar, I Quintus, Besselink, Marc Gh, Busch, Olivier Rc, Dijkgraaf, Marcel Gw, van Gulik, Thomas M, Coelen, Robert J S, Rauws, Erik A J, van Eijck, Casper H J, Dejong, Cornelis H C, Besselink, Marc G H, and Busch, Olivier R C
- Abstract
Background: Liver surgery in perihilar cholangiocarcinoma (PHC) is associated with high postoperative morbidity because the tumor typically causes biliary obstruction. Preoperative biliary drainage is used to create a safer environment prior to liver surgery, but biliary drainage may be harmful when severe drainage-related complications deteriorate the patients' condition or increase the risk of postoperative morbidity. Biliary drainage can cause cholangitis/cholecystitis, pancreatitis, hemorrhage, portal vein thrombosis, bowel wall perforation, or dehydration. Two methods of preoperative biliary drainage are mostly applied: endoscopic biliary drainage, which is currently used in most regional centers before referring patients for surgical treatment, and percutaneous transhepatic biliary drainage. Both methods are associated with severe drainage-related complications, but two small retrospective series found a lower incidence in the number of preoperative complications after percutaneous drainage compared to endoscopic drainage (18-25% versus 38-60%, respectively). The present study randomizes patients with potentially resectable PHC and biliary obstruction between preoperative endoscopic or percutaneous transhepatic biliary drainage.Methods/design: The study is a multi-center trial with an "all-comers" design, randomizing patients between endoscopic or percutaneous transhepatic biliary drainage. All patients selected to potentially undergo a major liver resection for presumed PHC are eligible for inclusion in the study provided that the biliary system in the future liver remnant is obstructed (even if they underwent previous inadequate endoscopic drainage). Primary outcome measure is the total number of severe preoperative complications between randomization and exploratory laparotomy. The study is designed to detect superiority of percutaneous drainage: a provisional sample size of 106 patients is required to detect a relative decrease of 50% in the number of severe preoperative complications (alpha = 0.95; beta = 0.8). Interim analysis after inclusion of 53 patients (50%) will provide the definitive sample size. Secondary outcome measures encompass the success of biliary drainage, quality of life, and postoperative morbidity and mortality.Discussion: The DRAINAGE trial is designed to identify a difference in the number of severe drainage-related complications after endoscopic and percutaneous transhepatic biliary drainage in patients selected to undergo a major liver resection for perihilar cholangiocarcinoma.Trial Registration: Netherlands Trial Register [ NTR4243 , 11 October 2013]. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
14. Impact of the COVID-19 pandemic on incidence and severity of acute appendicitis: a comparison between 2019 and 2020.
- Author
-
Scheijmans JCG, Borgstein ABJ, Puylaert CAJ, Bom WJ, Bachiri S, van Bodegraven EA, Brandsma ATA, Ter Brugge FM, de Castro SMM, Couvreur R, Franken LC, Gaspersz MP, de Graaff MR, Groenen H, Kleipool SC, Kuypers TJL, Martens MH, Mens DM, Orsini RG, Reneerkens NJMM, Schok T, Sedee WJA, Tavakoli Rad S, Volders JH, Weeder PD, Prins JM, Gietema HA, Stoker J, Gisbertz SS, Besselink MGH, and Boermeester MA
- Subjects
- Adult, Appendectomy, Female, Humans, Incidence, Male, Middle Aged, Netherlands epidemiology, Pandemics, Postoperative Complications epidemiology, Retrospective Studies, SARS-CoV-2, Severity of Illness Index, Time-to-Treatment, Appendicitis epidemiology, COVID-19 epidemiology
- Abstract
Background: During the COVID-19 pandemic, a decrease in the number of patients presenting with acute appendicitis was observed. It is unclear whether this caused a shift towards more complicated cases of acute appendicitis. We compared a cohort of patients diagnosed with acute appendicitis during the 2020 COVID-19 pandemic with a 2019 control cohort., Methods: We retrospectively included consecutive adult patients in 21 hospitals presenting with acute appendicitis in a COVID-19 pandemic cohort (March 15 - April 30, 2020) and a control cohort (March 15 - April 30, 2019). Primary outcome was the proportion of complicated appendicitis. Secondary outcomes included prehospital delay, appendicitis severity, and postoperative complication rates., Results: The COVID-19 pandemic cohort comprised 607 patients vs. 642 patients in the control cohort. During the COVID-19 pandemic, a higher proportion of complicated appendicitis was seen (46.9% vs. 38.5%; p = 0.003). More patients had symptoms exceeding 24 h (61.1% vs. 56.2%, respectively, p = 0.048). After correction for prehospital delay, presentation during the first wave of the COVID-19 pandemic was still associated with a higher rate of complicated appendicitis. Patients presenting > 24 h after onset of symptoms during the COVID-19 pandemic were older (median 45 vs. 37 years; p = 0.001) and had more postoperative complications (15.3% vs. 6.7%; p = 0.002)., Conclusions: Although the incidence of acute appendicitis was slightly lower during the first wave of the 2020 COVID-19 pandemic, more patients presented with a delay and with complicated appendicitis than in a corresponding period in 2019. Spontaneous resolution of mild appendicitis may have contributed to the increased proportion of patients with complicated appendicitis. Late presenting patients were older and experienced more postoperative complications compared to the control cohort.
- Published
- 2021
- Full Text
- View/download PDF
15. Early biliary decompression versus conservative treatment in acute biliary pancreatitis (APEC trial): study protocol for a randomized controlled trial.
- Author
-
Schepers NJ, Bakker OJ, Besselink MG, Bollen TL, Dijkgraaf MG, van Eijck CH, Fockens P, van Geenen EJ, van Grinsven J, Hallensleben ND, Hansen BE, van Santvoort HC, Timmer R, Anten MP, Bolwerk CJ, van Delft F, van Dullemen HM, Erkelens GW, van Hooft JE, Laheij R, van der Hulst RW, Jansen JM, Kubben FJ, Kuiken SD, Perk LE, de Ridder RJ, Rijk MC, Römkens TE, Schoon EJ, Schwartz MP, Spanier BW, Tan AC, Thijs WJ, Venneman NG, Vleggaar FP, van de Vrie W, Witteman BJ, Gooszen HG, and Bruno MJ
- Subjects
- Acute Disease, Cholangiography, Humans, Sample Size, Sphincterotomy, Endoscopic, Biliary Tract Surgical Procedures methods, Clinical Protocols, Decompression, Surgical methods, Pancreatitis surgery
- Abstract
Background: Acute pancreatitis is mostly caused by gallstones or sludge. Early decompression of the biliary tree by endoscopic retrograde cholangiography (ERC) with sphincterotomy may improve outcome in these patients. Whereas current guidelines recommend early ERC in patients with concomitant cholangitis, early ERC is not recommended in patients with mild biliary pancreatitis. Evidence on the role of routine early ERC with endoscopic sphincterotomy in patients without cholangitis but with biliary pancreatitis at high risk for complications is lacking. We hypothesize that early ERC with sphincterotomy improves outcome in these patients., Methods/design: The APEC trial is a randomized controlled, parallel group, superiority multicenter trial. Within 24 hours after presentation to the emergency department, patients with biliary pancreatitis without cholangitis and at high risk for complications, based on an Acute Physiology and Chronic Health Evaluation (APACHE-II) score of 8 or greater, Modified Glasgow score of 3 or greater, or serum C-reactive protein above 150 mg/L, will be randomized. In 27 hospitals of the Dutch Pancreatitis Study Group, 232 patients will be allocated to early ERC with sphincterotomy or to conservative treatment. The primary endpoint is a composite of major complications (that is, organ failure, pancreatic necrosis, pneumonia, bacteremia, cholangitis, pancreatic endocrine, or exocrine insufficiency) or death within 180 days after randomization. Secondary endpoints include ERC-related complications, infected necrotizing pancreatitis, length of hospital stay and an economical evaluation., Discussion: The APEC trial investigates whether an early ERC with sphincterotomy reduces the composite endpoint of major complications or death compared with conservative treatment in patients with biliary pancreatitis at high risk of complications., Trial Registration: Current Controlled Trials ISRCTN97372133 (date registration: 17-12-2012).
- Published
- 2016
- Full Text
- View/download PDF
16. Acute cholecystitis in high risk surgical patients: percutaneous cholecystostomy versus laparoscopic cholecystectomy (CHOCOLATE trial): study protocol for a randomized controlled trial.
- Author
-
Kortram K, van Ramshorst B, Bollen TL, Besselink MG, Gouma DJ, Karsten T, Kruyt PM, Nieuwenhuijzen GA, Kelder JC, Tromp E, and Boerma D
- Subjects
- Cholecystitis, Acute diagnosis, Cholecystitis, Acute economics, Cholecystitis, Acute mortality, Hospital Costs, Hospitals, Teaching, Humans, Length of Stay, Netherlands, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, Cholecystectomy, Laparoscopic adverse effects, Cholecystectomy, Laparoscopic economics, Cholecystectomy, Laparoscopic mortality, Cholecystitis, Acute surgery, Cholecystostomy adverse effects, Cholecystostomy economics, Cholecystostomy methods, Cholecystostomy mortality, Research Design
- Abstract
Background: Laparoscopic cholecystectomy in acute calculous cholecystitis in high risk patients can lead to significant morbidity and mortality. Percutaneous cholecystostomy may be an alternative treatment option but the current literature does not provide the surgical community with evidence based advice., Methods/design: The CHOCOLATE trial is a randomised controlled, parallel-group, superiority multicenter trial. High risk patients, defined as APACHE-II score 7-14, with acute calculous cholecystitis will be randomised to laparoscopic cholecystectomy or percutaneous cholecystostomy. During a two year period 284 patients will be enrolled from 30 high volume teaching hospitals. The primary endpoint is a composite endpoint of major complications within three months following randomization and need for re-intervention and mortality during the follow-up period of one year. Secondary endpoints include all other complications, duration of hospital admission, difficulty of procedures and total costs., Discussion: The CHOCOLATE trial is designed to provide the surgical community with an evidence based guideline in the treatment of acute calculous cholecystitis in high risk patients., Trial Registration: Netherlands Trial Register (NTR): NTR2666.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.